Empagliflozin, a novel potent and selective SGLT‐2 inhibitor, improves glycaemic control alone and in combination with insulin in streptozotocin‐induced diabetic rats, a model of type 1 diabetes mellitus
Year: 2012
Type: article
Source: Diabetes Obesity and Metabolism
Authors: G. Luippold, T. Klein, M. Mark, R. Grempler
Institution: Boehringer Ingelheim (Germany)
Language: English
Subfield: Endocrinology, Diabetes and Metabolism
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2068405048
